COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster dose
Sapir Dreyer-Alster,Shay Menascu,Mathilda Mandel,Emanuel Shirbint,David Magalashvili,Mark Doyle,Shlomo Flechter,Uri Givon,Diana Guber,Yael Stern,Shmuel Miron,Michael Polliack,Rina Falb,Polina Sonis,Michael Gurevich,Anat Achiron +15 more
Reads0
Chats0
TLDR
In this paper , the authors assessed the safety of the third dose of the BNT162b2-COVID-19 mRNA vaccination in adult MS patients and evaluated SARS-CoV-2 IgG response.About:
This article is published in Journal of the Neurological Sciences.The article was published on 2022-01-01 and is currently open access. It has received 42 citations till now. The article focuses on the topics: Medicine & Medicine.read more
Citations
More filters
Journal ArticleDOI
Humoral response after the booster dose of anti-SARS-CoV-2 vaccine in multiple sclerosis patients treated with high-efficacy therapies
Alessandro Maglione,Marta Morra,Raffaella Meroni,Manuela Matta,Marinella Clerico,Simona Rolla +5 more
TL;DR: In this paper , the authors evaluated the kinetics of the production of anti-receptor binding domain (RBD) Immunoglobulins G (IgG) after the vaccination cycle and the booster in pwMS receiving ocrelizumab, fingolimod and cladribine.
Journal ArticleDOI
Booster COVID-19 Vaccines for Immune-Mediated Inflammatory Disease Patients: A Systematic Review and Meta-Analysis of Efficacy and Safety
TL;DR: The results show that booster doses are effective in eliciting seroconversion in non-responders, bolstering immunity to COVID-19, and has also not been associated with major adverse events.
Journal ArticleDOI
Neuro-Ophthalmic Implications of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Related Infection and Vaccination
TL;DR: A review on the implications for neuro-ophthalmology drawn on resources presently available including reported adverse reactions to vaccination is presented in this article , where the most common conditions discussed relate to headaches and associated symptoms; vertigo, diplopia, and nystagmus; vascular complications of the eye and brain; cranial nerve (mono-)neuropathies; photophobia, ocular discomfort, and optic neuritis.
Journal ArticleDOI
SARS-CoV-2 vaccination in patients with multiple sclerosis in Germany and the United Kingdom: Gender-specific results from a longitudinal observational study
Niklas Frahm,Firas Fneish,David Ellenberger,Judith Haas,Micha Loebermann,Tina Parciak,Melanie Peters,Dieter Pöhlau,Jeff Rodgers,Anna-Lena Röper,Sarah Schilling,Alexander Stahmann,H. Temmes,Uwe K. Zettl,Rodden M. Middleton +14 more
TL;DR: The most common VRs were fatigue, headache, and pain (at the injection site) and occurred more often in women compared with men as discussed by the authors , while the most frequent deteriorated symptoms were fatigue and gait impairment.
Journal ArticleDOI
Long-term follow-up (up to 11 years) of an Italian pediatric MS cohort treated with Natalizumab: a multicenter, observational study
Damiano Baroncini,Angelo Ghezzi,Clara Guaschino,Lucia Moiola,Massimo Filippi,Antonio Ianniello,Carlo Pozzilli,Roberta Lanzillo,Vincenzo Bresciamorra,Monica Margoni,Paolo Gallo,Graziella Callari,Luigi M.E. Grimaldi,Giacomo Lus,Massimiliano Calabrese,Marta Simone,Girolama Alessandra Marfia,Sarah Rasia,Daniela Cargnelutti,Giancarlo Comi,Mauro Zaffaroni,Maria Trojano,Diego Centonze,Ruggero Capra,Marco Capobianco,Alice Laroni,Antonio Uccelli,Antonio Gallo,Francesco Patti,M. Danni,Claudio Gasperini,G. Coniglio +31 more
TL;DR: In this paper , the authors report long-term follow-up data (up to 11 years) of a large Italian pediatric multiple sclerosis (MS) cohort treated with NAT, with no difference in safety profile compared to adult MS.
References
More filters
Journal ArticleDOI
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
Fernando P. Polack,Stephen J. Thomas,Nicholas Kitchin,Judith Absalon,Alejandra Gurtman,Stephen Lockhart,John L. Perez,Gonzalo Pérez Marc,Edson D. Moreira,Cristiano Zerbini,Ruth Bailey,Kena A. Swanson,Satrajit Roychoudhury,Kenneth Koury,Ping Li,Warren Kalina,David A. Cooper,Robert W. Frenck,Laura L. Hammitt,Özlem Türeci,Haylene Nell,Axel Schaefer,Serhat Ünal,Dina B. Tresnan,Susan Mather,Philip R. Dormitzer,Ugur Sahin,Kathrin U. Jansen,William C. Gruber +28 more
TL;DR: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older and safety over a median of 2 months was similar to that of other viral vaccines.
Journal ArticleDOI
Covid-19 Breakthrough Infections in Vaccinated Health Care Workers.
Moriah Bergwerk,Tal Gonen,Yaniv Lustig,Sharon Amit,Marc Lipsitch,Carmit Cohen,Michal Mandelboim,Einav G Levin,Carmit Rubin,Victoria Indenbaum,Ilana Tal,Malka Zavitan,Neta S. Zuckerman,Adina Bar-Chaim,Yitshak Kreiss,Gili Regev-Yochay +15 more
TL;DR: Despite the high efficacy of the BNT162b2 messenger RNA vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), rare breakthrough infections have been reported.
Journal ArticleDOI
Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel.
Yinon M. Bar-On,Yair Goldberg,Micha Mandel,Omri Bodenheimer,Laurence Freedman,Nir Kalkstein,Barak Mizrahi,Sharon Alroy-Preis,Nachman Ash,Ron Milo,Amit Huppert +10 more
TL;DR: In this paper, the authors investigated the effect of the booster dose on the rate of confirmed coronavirus 2019 disease (Covid-19) and the rates of severe illness.
Journal ArticleDOI
Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy.
Sokratis A. Apostolidis,Mihir Kakara,Mark M Painter,Rishi R. Goel,Divij Mathew,Kerry Lenzi,Ayman Rezk,Kristina R. Patterson,Diego A. Espinoza,Jessy C. Kadri,Daniel M. Markowitz,Clyde E. Markowitz,Ina Mexhitaj,Dina A. Jacobs,Allison Babb,Michael R. Betts,Eline T. Luning Prak,Daniela Weiskopf,Alba Grifoni,Kendall A. Lundgreen,Sigrid Gouma,Alessandro Sette,Alessandro Sette,Paul Bates,Scott E. Hensley,Allison R. Greenplate,E. John Wherry,Rui Li,Amit Bar-Or +28 more
TL;DR: In this article, an anti-CD20 monoclonal antibody (aCD20) was used to reduce spike-specific and receptor-binding domain (RBD)-specific antibody and memory B cell responses in most patients.
Journal ArticleDOI
COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021.
Anat Achiron,Mark Dolev,Shay Menascu,Daniela Noa Zohar,Sapir Dreyer-Alster,Shmuel Miron,Emanuel Shirbint,David Magalashvili,Shlomo Flechter,Uri Givon,Diana Guber,Yael Stern,Michael Polliack,Rina Falb,Michael Gurevich +14 more
TL;DR: In this article, risks related to vaccinating patients with multiple sclerosis (MS) need to be carefully assessed, since vaccination against coronavirus disease 2019 (COVID-19) became available.
Related Papers (5)
Mucosal immune responses to pneumococcal polysaccharides: implications for vaccination
Development of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients After 1273-mRNA SARS-CoV-2 Vaccination
Maria Gonzalez-Perez,María Montes-Casado,Patricia Conde,Isabel Cervera,Jana Baranda,Marcos J. Berges-Buxeda,Mayte Pérez-Olmeda,Rodrigo Sanchez-Tarjuelo,Alberto Utrero-Rico,Daniel Lozano-Ojalvo,Denisse P. Rivera de la Torre,Megan C. Schwarz,Ernesto Guccione,Carmen Camara,M. Rosario Llópez-Carratalá,Emilio González-Parra,Pilar Portolés,Alberto Ortiz,José Portolés,Jordi Ochando +19 more